Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, October 25 '25)

Image
By G.M.

 


    Antiviral Res

  1. BESSONNE M, Morel J, Nevers Q, Groutsch J, et al
    Inhibition of influenza virus replication by artificial proteins (alphaReps) targeting its RNA-polymerase.
    Antiviral Res. 2025 Oct 21:106300. doi: 10.1016/j.antiviral.2025.106300.
    PubMed         Abstract available


    BMC Pediatr

  2. WONG K, Ducharme R, Murphy MSQ, Clarke AE, et al
    SARS-CoV-2 infection in pregnancy and infant outcomes in the first year of life: a retrospective cohort study.
    BMC Pediatr. 2025;25:842.
    PubMed         Abstract available

  3. MAGGIO ABR, Palomo S, Joye R, Huguet H, et al
    Reduced aerobic capacity in children with multisystem inflammatory syndrome in children (MIS-C) after PICU admission: a retrospective cohort study, 2020-2022.
    BMC Pediatr. 2025;25:835.
    PubMed         Abstract available


    Cell

  4. HICKMAN HD, Moutsopoulos NM
    Don't forget to floss! An innovative approach for vaccine delivery.
    Cell. 2025;188:5787-5789.
    PubMed         Abstract available


    Epidemiol Infect

  5. GODOY P, Pardos J, Garcia Cenoz M, Parron I, et al
    Mask wearing by COVID-19 index cases reduces SARS-CoV-2 transmission to household contacts.
    Epidemiol Infect. 2025;153:e125.
    PubMed         Abstract available


    J Clin Microbiol

  6. BACSIK DJ, Mills MG, Monroe LD, Spring C, et al
    Validation of H5 influenza virus subtyping RT-qPCR assay and low prevalence of H5 detection in 2024-2025 influenza virus season.
    J Clin Microbiol. 2025 Oct 21:e0041525. doi: 10.1128/jcm.00415.
    PubMed         Abstract available


    J Gen Virol

  7. SHIMOTAI Y, Sugawara K, Matsuzaki Y, Muraki Y, et al
    Cytoplasmic domain of CM2 is involved in the replication of influenza C virus.
    J Gen Virol. 2025;106:002165.
    PubMed         Abstract available


    J Infect

  8. MOORE CM, Secor EA, Fairbanks-Mahnke A, Everman JL, et al
    Independent and interactive effects of viral species on early-life lower respiratory tract illness.
    J Infect. 2025 Sep 25:106616. doi: 10.1016/j.jinf.2025.106616.
    PubMed         Abstract available

  9. RAJAN A, Nagaraj D, Bomidi C, Aloisio GM, et al
    Single cell sequencing analysis of respiratory syncytial virus-infected pediatric and adult human nose organoids reveals age differences, proliferative diversity and identifies novel cellular tropism.
    J Infect. 2025;91:106617.
    PubMed         Abstract available

  10. GRANVIK C, Persson IL, Barros GWF, Ahlm C, et al
    Long-term Physical Capacity Following COVID-19: A Prospective, Three-Year Study.
    J Infect. 2025 Sep 12:106614. doi: 10.1016/j.jinf.2025.106614.
    PubMed         Abstract available

  11. PRITCHARD E, Vihta KD, Lipworth S, Pouwels KB, et al
    An Electronic Health Record-Wide Association Study to identify populations at increased risk of E. coli bloodstream infections.
    J Infect. 2025 Sep 3:106612. doi: 10.1016/j.jinf.2025.106612.
    PubMed         Abstract available


    J Virol

  12. JOSEPH R, Marais G, Iranzadeh I, Alisoltani A, et al
    Intra-host SARS-CoV-2 diversity in immunocompromised people living with HIV provides insight into the evolutionary trajectory of SARS-CoV-2.
    J Virol. 2025 Sep 5:e0078025. doi: 10.1128/jvi.00780.
    PubMed         Abstract available

  13. WANG J, Sang X, Zheng W, Chan JF-W, et al
    Discovery of a potent covalent inhibitor that unusually distorts the catalytic dyad of SARS-CoV-2 main protease.
    J Virol. 2025 Sep 15:e0065825. doi: 10.1128/jvi.00658.
    PubMed         Abstract available

  14. FARRUKEE R, Mordant F, Mackenzie-Kludas C, Mesner D, et al
    Human guanylate-binding protein (GBP) 1 inhibits replication of severe acute respiratory syndrome coronavirus 2.
    J Virol. 2025 Sep 15:e0082325. doi: 10.1128/jvi.00823.
    PubMed         Abstract available

  15. RZYMSKI P, Poniedzialek B, Zarebska-Michaluk D, Tomasiewicz K, et al
    High seroprevalence and high risk: why are older adults more prone to respiratory syncytial virus?
    J Virol. 2025;99:e0143225.
    PubMed         Abstract available

  16. CHIOK KL, Jenik K, Fenton M, Falzarano D, et al
    MERS-CoV and SARS-CoV-2 infection in diverse human lung organoid-derived cultures.
    J Virol. 2025 Sep 18:e0109825. doi: 10.1128/jvi.01098.
    PubMed         Abstract available

  17. HAMMER E, Flynn C, Rossler J, Erder J, et al
    Prediction of COVID-19 disease progression by multiparametric analysis of circulating extracellular vesicles with flow cytometry.
    J Virol. 2025 Sep 23:e0118925. doi: 10.1128/jvi.01189.
    PubMed         Abstract available

  18. TSUJINO S, Tsuda M, Nao N, Okumura K, et al
    Evolution of BA.2.86 to JN.1 reveals that functional changes in non-structural viral proteins are required for fitness of SARS-CoV-2.
    J Virol. 2025 Sep 23:e0090825. doi: 10.1128/jvi.00908.
    PubMed         Abstract available

  19. SHU T, Wang X, Li Y, Su J, et al
    Respiratory syncytial virus phosphoprotein has NTPase and helicase-like activities.
    J Virol. 2025;99:e0099625.
    PubMed         Abstract available

  20. SUN L, Huang M, Feng S, Zhang W, et al
    Developing an eVLP mRNA vaccine for respiratory syncytial virus with enhanced pre-fusion targeting humoral responses.
    J Virol. 2025 Sep 30:e0120925. doi: 10.1128/jvi.01209.
    PubMed         Abstract available

  21. PAN Z, Jiang L, Chen Y, Peng H, et al
    Adjuvant-dependent protection of SARS-CoV-2 spike vaccines: comparative immunogenicity of human-applicable formulations.
    J Virol. 2025 Oct 3:e0109925. doi: 10.1128/jvi.01099.
    PubMed         Abstract available


    J Virol Methods

  22. AFZAL M, Willcox MDP, Praet S, Mcdonald M, et al
    Evaluating the effectiveness of a novel environmental decontamination system utilizing low-energy hyper-charged photoelectrons against coronavirus.
    J Virol Methods. 2026;339:115269.
    PubMed         Abstract available

  23. HINOJOSA-TRUJILLO D, Dehesa-Canseco F, Garcia-Vega M, Mata-Haro V, et al
    Evaluation of two IgG-scFv bispecific antibodies for neutralizing Omicron variants of SARS-CoV-2.
    J Virol Methods. 2026;339:115258.
    PubMed         Abstract available

  24. BRAVI ME, Fuentealba NA, Brasso N, Sguazza GH, et al
    Performance evaluation of a SYBR Green-based real-time quantitative PCR for SARS-CoV-2 detection from animal oropharyngeal samples.
    J Virol Methods. 2026;339:115259.
    PubMed         Abstract available

  25. CHEN Y, Zhang T, Zhang J, Dong X, et al
    Comparative effects of three SARS-CoV-2 inactivation methods on cytokine detection using LEGENDplex bead-based immunoassays.
    J Virol Methods. 2026;339:115244.
    PubMed         Abstract available


    Lancet


  26. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Stud
    Lancet. 2025 Oct 12:S0140-6736(25)01637-X. doi: 10.1016/S0140-6736(25)01637.
    PubMed         Abstract available


  27. Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950-2023: a demographic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Oct 12:S0140-6736(25)01330-3. doi: 10.1016/S0140-6736(25)01330.
    PubMed         Abstract available

  28. JOHANSEN ND, Modin D, Pardo-Seco J, Rodriguez-Tenreiro-Sanchez C, et al
    Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysis.
    Lancet. 2025 Oct 17:S0140-6736(25)01742-8. doi: 10.1016/S0140-6736(25)01742.
    PubMed         Abstract available


    N Engl J Med

  29. SIEGERS JY, Xie R, Edwards KM, Byrne AMP, et al
    Resurgence of Zoonotic Highly Pathogenic Avian Influenza A(H5N1) Virus in Cambodia.
    N Engl J Med. 2025;393:1650-1652.
    PubMed        

  30. CAI M, Xie Y, Al-Aly Z
    Association of 2024-2025 Covid-19 Vaccine with Covid-19 Outcomes in U.S. Veterans.
    N Engl J Med. 2025 Oct 8. doi: 10.1056/NEJMoa2510226.
    PubMed         Abstract available


    PLoS One

  31. HEMATRAM YADAV RY, Thangiah N, Bhaskaran KS, Kumarasamy C, et al
    Factors associated with hospitalization of people with influenza in a Malaysian tertiary hospital from 2015 to 2019.
    PLoS One. 2025;20:e0333921.
    PubMed         Abstract available

  32. ABIDIN FA, Prathama AG, Fitriana E, Mayangsari A, et al
    Depression, anxiety, and stress levels during the COVID-19 pandemic: A longitudinal study among Indonesian psychologists.
    PLoS One. 2025;20:e0315584.
    PubMed         Abstract available

  33. CATALFAMO CJ, Jacobs ET, Falk LP, Lauro P, et al
    Concordance between self-reported SARS-CoV-2 positivity and laboratory-confirmed positivity.
    PLoS One. 2025;20:e0334102.
    PubMed         Abstract available

  34. KALIA V, Knauft K
    Adults with adverse childhood experiences report greater coronavirus anxiety.
    PLoS One. 2025;20:e0323401.
    PubMed         Abstract available

  35. KUCHLER J, Zinnecker T, Hellwig P, Wolf M, et al
    Quantitative analysis of proteomic changes in two monoclonal suspension MDCK cell lines infected with human influenza A virus (H1N1).
    PLoS One. 2025;20:e0327939.
    PubMed         Abstract available

  36. HOLZER A, Stoever A, Lau M, Gleich S, et al
    Quantitative and qualitative changes in substance-related administrative offences in road traffic during the SARS-CoV-2 pandemic in Munich.
    PLoS One. 2025;20:e0334598.
    PubMed         Abstract available

  37. BALECH B, Lo Presti A, Telegrafo C, Maisto L, et al
    Investigating the evolutionary dynamics and mutational pattern of SARS-CoV-2 spike gene on selected SARS-CoV-2 variants.
    PLoS One. 2025;20:e0333093.
    PubMed         Abstract available

  38. MAKI K
    Methodology for predicting hospital admissions and evaluating recovery rates for coronavirus disease in Japan.
    PLoS One. 2025;20:e0334643.
    PubMed         Abstract available

  39. DELAVARY M, Kalantari AH, Farsangi H, Mohammadzadeh Moghaddam A, et al
    Effect of COVID-19 restrictions and fuel prices on traffic volume and offenses in Iran: A spatiotemporal analysis.
    PLoS One. 2025;20:e0332443.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  40. FORMIGA RO, Pesenti L, de la Heronniere FC, Ladjemi MZ, et al
    Cytosolic proliferating cell nuclear antigen (PCNA) orchestrates neutrophil hyperactivation in COVID-19.
    Proc Natl Acad Sci U S A. 2025;122:e2503667122.
    PubMed         Abstract available


    Vaccine

  41. CHAUDHRY T, Tum P, Morrow F, Hargreaves S, et al
    Facilitators to strengthening vaccine uptake post-pandemic amongst underserved populations considering social norms and health beliefs: a global systematic review.
    Vaccine. 2025;65:127769.
    PubMed         Abstract available

  42. ZEEVAT F, Luttjeboer J, Korsten K, van Boven M, et al
    Evaluating cost-effectiveness of RSV vaccination strategies for older adults in the Netherlands.
    Vaccine. 2025;65:127735.
    PubMed         Abstract available

  43. CAMPBELL PM, Ess GJ, Lale A, Talaat KR, et al
    Clinical immunization safety assessment (CISA) project: COVID-19 vaccine consultations and case reviews.
    Vaccine. 2025;65:127781.
    PubMed         Abstract available

  44. DOMINGUEZ ISLAS CP, Magaret CA, Molitor C, Serebryannyy L, et al
    SARS-CoV-2 spike sequence-based distance as a marker of binding antibody response to COVID-19 vaccines.
    Vaccine. 2025;65:127738.
    PubMed         Abstract available

  45. OPHIR Y, Wong JH, Haddad KR, Huuskonen A, et al
    Expression and characterization of SARS-CoV-2 spike protein in Thermothelomyces heterothallica C1.
    Vaccine. 2025;65:127784.
    PubMed         Abstract available

  46. WROBLEWSKI M, Meler A
    Vaccine acceptance and refusal in Western and Central and Eastern European countries: An analysis based on the European Social Survey data from 23 countries, using a classification and regression tree.
    Vaccine. 2025;65:127807.
    PubMed         Abstract available

  47. FANG X, Holding AC, Audet EC, Thai H, et al
    Understanding COVID-19 vaccination disparity among Black adults in North America: A two-study motivational approach.
    Vaccine. 2025;65:127803.
    PubMed         Abstract available

  48. OGATA T, Hattori S, Kawachi K, Ishikane M, et al
    Durability of effectiveness of a booster dose of COVID-19 bivalent (ancestral/BA.4-5) vaccine against all-cause mortality in older adults in Japan, October 2022 to September 2023.
    Vaccine. 2025;65:127796.
    PubMed         Abstract available

  49. HIRAGA K, Momose H, Kuribayashi W, Uemura M, et al
    Development of a novel safety assessment method for quality control of mRNA vaccines based on lung biomarker gene expression.
    Vaccine. 2025;65:127805.
    PubMed         Abstract available

  50. BLADH O, Aguilera K, Sheikh-Mohamed S, Nardulli J, et al
    Comparing methods collecting mucosal secretions and detecting SARS-CoV-2 spike IgA in three laboratories across three countries.
    Vaccine. 2025;65:127792.
    PubMed         Abstract available


    Virology

  51. TSUNEKI-TOKUNAGA A, Komatsu M, Perdana WY, Nishiyama S, et al
    Epidemic influenza virus strains with high growth capability induce severe inflammatory response in vivo.
    Virology. 2025;613:110717.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »